Pancreatic α- and β-cell responses to GIP infusion in normal man

D. Elahi, Dana Andersen, J. C. Brown

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Evidence is increasing that the major gut hormone responsible for augmentation of insulin secretion is gastric inhibitory polypeptide (GIP). Further understanding of the role of GIP on the function of α- and β-cells of the pancreas and the dependence of this interaction on the ambient glucose concentration can be gained from the application of the glucose-clamp technique. Highly purified porcine GIP was administered intravenously at a dose of 6.7 ng/(kg X min) for 90 min under the following conditions: A) during basal-state euglycemia, B) after the establishment of mild, steady-state hyperglycemia at a plasma glucose level 54 mg/dl above basal, and C) after the establishment of moderate, steady-state hyperglycemia at a plasma glucose level of 143 mg/dl above basal. In all 3 conditions, plasma GIP levels were within the physiological range. Under condition A, no changes in plasma immunoreactive insulin (IRI), immunoreactive glucagon (IRG), or glucose were observed. Under condition B, IRG was suppressed by the hyperglycemia and no further effect was observed during or after the GIP infusion. IRI levels were modestly augmented. Under condition C, IRG responded as in condition B. IRI levels in condition C, however, were markedly elevated by GIP infusion. Biological half-life of GIP ranged from 13 to 26 min under the conditions of these studies. We conclude that GIP, whether endogenously released or exogenously administered in physiological concentrations, is a gastrointestinal mediator of insulin release; its effect is dependent on the ambient blood glucose level. Furthermore, GIP is not glucagonotropic in normal man during either euglycemic or hyperglycemic conditions.

Original languageEnglish (US)
JournalAmerican Journal of Physiology Endocrinology Metabolism and Gastrointestinal Physiology
Volume6
Issue number2
StatePublished - 1979
Externally publishedYes

Fingerprint

Gastric Inhibitory Polypeptide
Glucagon
Hyperglycemia
Insulin
Glucose
Glucose Clamp Technique
Half-Life
Blood Glucose
Pancreas
Swine
Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{8bfdd7047a234650a6d787f6f115dc8b,
title = "Pancreatic α- and β-cell responses to GIP infusion in normal man",
abstract = "Evidence is increasing that the major gut hormone responsible for augmentation of insulin secretion is gastric inhibitory polypeptide (GIP). Further understanding of the role of GIP on the function of α- and β-cells of the pancreas and the dependence of this interaction on the ambient glucose concentration can be gained from the application of the glucose-clamp technique. Highly purified porcine GIP was administered intravenously at a dose of 6.7 ng/(kg X min) for 90 min under the following conditions: A) during basal-state euglycemia, B) after the establishment of mild, steady-state hyperglycemia at a plasma glucose level 54 mg/dl above basal, and C) after the establishment of moderate, steady-state hyperglycemia at a plasma glucose level of 143 mg/dl above basal. In all 3 conditions, plasma GIP levels were within the physiological range. Under condition A, no changes in plasma immunoreactive insulin (IRI), immunoreactive glucagon (IRG), or glucose were observed. Under condition B, IRG was suppressed by the hyperglycemia and no further effect was observed during or after the GIP infusion. IRI levels were modestly augmented. Under condition C, IRG responded as in condition B. IRI levels in condition C, however, were markedly elevated by GIP infusion. Biological half-life of GIP ranged from 13 to 26 min under the conditions of these studies. We conclude that GIP, whether endogenously released or exogenously administered in physiological concentrations, is a gastrointestinal mediator of insulin release; its effect is dependent on the ambient blood glucose level. Furthermore, GIP is not glucagonotropic in normal man during either euglycemic or hyperglycemic conditions.",
author = "D. Elahi and Dana Andersen and Brown, {J. C.}",
year = "1979",
language = "English (US)",
volume = "6",
journal = "American Journal of Physiology Endocrinology Metabolism and Gastrointestinal Physiology",
issn = "0363-6100",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Pancreatic α- and β-cell responses to GIP infusion in normal man

AU - Elahi, D.

AU - Andersen, Dana

AU - Brown, J. C.

PY - 1979

Y1 - 1979

N2 - Evidence is increasing that the major gut hormone responsible for augmentation of insulin secretion is gastric inhibitory polypeptide (GIP). Further understanding of the role of GIP on the function of α- and β-cells of the pancreas and the dependence of this interaction on the ambient glucose concentration can be gained from the application of the glucose-clamp technique. Highly purified porcine GIP was administered intravenously at a dose of 6.7 ng/(kg X min) for 90 min under the following conditions: A) during basal-state euglycemia, B) after the establishment of mild, steady-state hyperglycemia at a plasma glucose level 54 mg/dl above basal, and C) after the establishment of moderate, steady-state hyperglycemia at a plasma glucose level of 143 mg/dl above basal. In all 3 conditions, plasma GIP levels were within the physiological range. Under condition A, no changes in plasma immunoreactive insulin (IRI), immunoreactive glucagon (IRG), or glucose were observed. Under condition B, IRG was suppressed by the hyperglycemia and no further effect was observed during or after the GIP infusion. IRI levels were modestly augmented. Under condition C, IRG responded as in condition B. IRI levels in condition C, however, were markedly elevated by GIP infusion. Biological half-life of GIP ranged from 13 to 26 min under the conditions of these studies. We conclude that GIP, whether endogenously released or exogenously administered in physiological concentrations, is a gastrointestinal mediator of insulin release; its effect is dependent on the ambient blood glucose level. Furthermore, GIP is not glucagonotropic in normal man during either euglycemic or hyperglycemic conditions.

AB - Evidence is increasing that the major gut hormone responsible for augmentation of insulin secretion is gastric inhibitory polypeptide (GIP). Further understanding of the role of GIP on the function of α- and β-cells of the pancreas and the dependence of this interaction on the ambient glucose concentration can be gained from the application of the glucose-clamp technique. Highly purified porcine GIP was administered intravenously at a dose of 6.7 ng/(kg X min) for 90 min under the following conditions: A) during basal-state euglycemia, B) after the establishment of mild, steady-state hyperglycemia at a plasma glucose level 54 mg/dl above basal, and C) after the establishment of moderate, steady-state hyperglycemia at a plasma glucose level of 143 mg/dl above basal. In all 3 conditions, plasma GIP levels were within the physiological range. Under condition A, no changes in plasma immunoreactive insulin (IRI), immunoreactive glucagon (IRG), or glucose were observed. Under condition B, IRG was suppressed by the hyperglycemia and no further effect was observed during or after the GIP infusion. IRI levels were modestly augmented. Under condition C, IRG responded as in condition B. IRI levels in condition C, however, were markedly elevated by GIP infusion. Biological half-life of GIP ranged from 13 to 26 min under the conditions of these studies. We conclude that GIP, whether endogenously released or exogenously administered in physiological concentrations, is a gastrointestinal mediator of insulin release; its effect is dependent on the ambient blood glucose level. Furthermore, GIP is not glucagonotropic in normal man during either euglycemic or hyperglycemic conditions.

UR - http://www.scopus.com/inward/record.url?scp=0018291929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018291929&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018291929

VL - 6

JO - American Journal of Physiology Endocrinology Metabolism and Gastrointestinal Physiology

JF - American Journal of Physiology Endocrinology Metabolism and Gastrointestinal Physiology

SN - 0363-6100

IS - 2

ER -